Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsProtein therapeutics continue to deliver groundbreaking solutions in oncology, autoimmune diseases, and immune-oncology, showing remarkable efficacy. However, managing immunological reactions to these biological treatments remains a significant challenge for developers. Rigorous evaluation methods are crucial for assessing T cell-dependent immunogenicity throughout both clinical and preclinical development phases. Creative Biolabs provides a comprehensive overview of current immunogenicity assessment methods, demonstrating expertise in the field.
The process of determining whether therapeutic biologics are immunogenic involves assessing their capacity to cause an immunological response in patients, namely the formation of anti-drug antibodies (ADAs). While some degree of intrinsic immunogenicity is present in all biologics, this assessment is required to determine the danger level since increased immunology can adversely impact a drug's security and efficacy profile, potentially leading to serious clinical repercussions. In silico prediction, in vivo models, and in vitro/ex vivo experiments are usually used in immunogenicity evaluation.
Antibodies against drugs can be produced naturally during treatment, resulting in an immune response with effects ranging from erythrocyte hypoplasia and severe deficiency syndrome to pharmacological minimization and hypersensitive infusion responses. Because of these serious effects, health authorities around the world have issued comprehensive recommendations for assessing immune activity.
Based on the principle of progressive progression, biosimilar drugs must be similar to the reference drug in terms of physical and chemical properties, biological activity, pharmacokinetics, efficacy and safety. Disturbingly, approved biologics often exhibit immunogenicity, highlighting the importance of preliminary studies for immunogenicity prediction. However, to understand how biologic drugs produce immunogenicity, researchers need a deeper understanding of T-cell-dependent immune responses. In risk assessment, developing robust methods to predict T-cell-dependent immune responses is increasingly important for protein therapy.
Fig. 1 Risk factors for immunogenicity during discovery to commercialization of biologics.1
As some patents for original biological drugs such as monoclonal antibodies expire, and the clinical demand for these medications escalates, the focus on biosimilar drug research and development has intensified. Consequently, the utilization of silicon models to predict immunogenicity has become an area of significant interest. These models are mainly used early in the drug development process to circumvent some of the adverse immune reactions in the later clinical stage.
Digital immunogenicity assessment aligns protein sequences and identifies possible T cell epitopes that could trigger an immune response. Commonly, these silicon immunogenicity assessments occur in the preliminary stages of the drug development lifecycle. They offer critical support for decision-making processes by identifying potential immunogenic dangers. This early evaluation facilitates the modification or transformation of the core immunogenic sequence, enabling us to achieve successful clinical results. Creative Biolabs has successfully established its proprietary Sensitive Immunoassay Technology® (SIAT®) system.
The first steps in biotherapeutic development involve the evaluation of immunogenic potential, often achieved through employable computational techniques known as in silico prediction. However, the complexity of biological systems and the broad range of possible immune responses can sometimes undermine the accuracy of these predictions. To address the problem, in vitro assays are used as a crucial tool in immunogenicity risk assessment, supplementing the theoretical predictions of in silico analysis. These tests mainly aim to predict the likelihood of T-cell immune responses. The advantage of in vitro immunogenicity testing, compared to in vivo testing, is that it allows for control, specificity, and quick evaluations.
The assessment of the T-cell-mediated immune response includes the probable binding of peptides created by T-cell proteins and human leukocyte antigen (HLA). The HLA often binds peptides, and this binding activity is necessary as a yardstick for subsequent T-cell trigger reactions of the immune system.
Investigation of the first potential epitopes identified by digital means is at the center of attention with binding assays. The specificity of the interrelation of HLA molecules and protein represents overlap of potential immune system reactions. Although such data presented by the assays do not make an unambiguously valid claim of immune responses, it is enriched by researchers' observations of potential immunogenicity linked to therapeutic candidates. Due to the incredible rate at which this has been in work, and by the large acceptance and use of the Multimeric MHC/Peptide Nationals Immune Monitoring Standards (NIMS), the platform is basically stamped with approval by the National Institute of Health.
Besides that, another solid stratum rests on the mitigation stratagem against immunogenicity threats: T-cell activation tests enable the prediction of possible immunogenicity. The main reason pertains to verifying whether a peptide is able to cause multiplication and/or stimulation of T cells in the long run. The information alerts potential threats associated with T-cell dependent immune responses occurring in living systems.
View Creative Biolabs in vitro immunogenicity assessment services:
In Vitro Class II HLA Binding Assay
In Vitro Human Systems
Therapeutic proteins represent an extremely complex entity, and ideally, a combination of computational analysis and HLA binding studies offers an efficient way of teasing out likely epitopes. Although this method is not always reliable, it is an important way to understand the potential of drug treatment.
It's time to say goodbye to in vitro validation methods, and the journey of T-cell activation testing continues. HLA transgenic mouse models and humanized mouse models can be used in vivo to evaluate the therapeutic effect of biologic drugs. This marks the potential to awaken a risk for T-cell-dependent immune responses in the living body and predicate likely immunogenicity.
View Creative Biolabs in vivo immunogenicity assessment services:
Ex Vivo Immunogenicity Assessment
In Vivo Immunogenicity Assessment
Biotherapeutic compounds, as they transfer into the host, carry the risk of not being recognized by the host's immunological defense system as exogenous invaders, thereby triggering an inherent immunological response that will create estimated ADAs. The resultant antibodies, therefore, have the capability of neutralizing the curative potential of the applied drugs through speeding up drug removal from the body, modulating the pharmacokinetic or pharmacodynamic profiles, or even provoking hyper sensitive reactions.
The proliferation of ADAs in patients can vary, marked between one and another by individual age and sex health difference, by genetic difference among patients, and by influencing agents like dosage, frequency, and even the method of drug administration, emphasizing the necessity for relentless vigilance, which may extend to monitoring ADA reactions throughout the course of treatment. For the old ADAs, potency varies based on the patient's own individuality, the unique genomic print, the personal medical history weighted by age and gender, with the dose and also the technique of administration of the drug being variables that manipulate and mold the production of ADAs. Thus, the continuing vigilant eye kept over the ADA cascade during the course of therapy becomes closer to a non-negotiable necessity than just preferred practice.
The immunological esoteric sphere beholds considerable buoyancy in instrumenting ways to detect these elusive ADAs, shapeshifters that they are. It comes to life as a glinting bow of techniques laid against the landscape, with each being a new hue in the detection spectrum, from the enzyme-linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA) traversing to the realms of surface plasmon resonance (SPR) and electrochemiluminescence (ECL) to sprinkle at the pot of gold in advanced incarnations like immune PCR(Im-PCR) and nimble methods in microfluidics.
Creative Biolabs is at the summit of the roof of immunogenicity assessment techniques and machines with the constant leveraging of unique pioneering advancements, resulting in an overall leveraged strategy for biotherapeutic development. Tactical planning takes root right in the early genesis of a project with inciting rationale for target modulation twinned along with the potential prototype molecule. Creative Biolabs uses a combination of in silico predictions, along with HLA binding assays, in such an enriched way that it provides authentic deductions woven into the preclinical tapestry of drug development about a prospective drug candidate.
Truly, this is where Creative Biolabs' art lies: in the translation of pharmacokinetic/pharmacodynamic assessments, toxicology, and preclinical efficacy into an integrative knowledge of the threats that may loom over a new therapeutic protein. In such a way, massive threats with an all-inclusive paradigm can be evaluated or discerned, hence allowing for a creative chart in designing the sequences of a protein, therefore making them less likely to be at jeopardy. Seemingly, this way, sequences that are strategically de-risked are advanced and stand against the correlative stumbling challenges.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
